As per reports, Microsoft (MSFT) released Q2 earnings ended December 31 missing Wall Street’s expectations.
Quarter Highlights:
- Adjusted Earnings per share of $2.32 per share was reported, versus $2.29 per share expected.
- Revenue of $52.75 billion was reported, versus $52.94 billion estimated.
- Net income dropped to $16.43 billion from $18.77 billion in the year-ago quarter.
- The company took a $1.2 billion charge in the quarter in connection with its decision to cut 10,000 jobs, revise its hardware lineup and consolidate leases. The charge includes $800 million in employee severance costs.
- Revenue in Microsoft’s Intelligent Cloud segment amounted to $21.51 billion, up 18% and slightly above the $21.44 billion estimates. The unit includes the Azure public cloud, Windows Server, SQL Server, Nuance and Enterprise Services.
- Revenue from Azure and other cloud services grew by 31%, slightly above the average estimate of just under 31%. In the previous quarter, the category grew 35%.
- The Productivity and Business Processes unit including Microsoft 365, LinkedIn and Dynamics, delivered $17 billion in revenue, up by 7% and exceeding estimates of $16.79 billion.
- The More Personal Computing segment featuring Windows, Xbox, Surface and search advertising contributed $14.24 billion, representing a revenue decline of 19%.
- Sales of Windows licenses to device makers declined 39% year over year, worsening from a decline of 15% from previous quarter.
Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses supports, and sells computer software, consumer electronics, personal computers, and related services. To learn more about Microsoft (MSFT) and to track their progress please visit the Vista Partners Coverage Page.
DID YOU KNOW?
Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).
If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.
INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
